BON Announces Unlocking Broccoli's Nutritional Power: Advanced Delivery System for Glucoraphanin Activation
Bon Natural Life (Nasdaq: BON) has announced a breakthrough in broccoli-derived nutrition with their patent-pending Glucoraphanin-Myrosinase co-delivery system. This biotech innovation enhances the bio-activity of glucoraphanin, a key compound in broccoli that converts to sulforaphane.
The technology addresses the previously inefficient conversion process of glucoraphanin to sulforaphane, which is known for its anti-cancer, sleep improvement, neuroprotective, digestive enhancement, anti-inflammatory, antioxidant, and anti-aging properties. The company's solution ensures optimal enzymatic activation within the body, achieving higher conversion efficiency to bio-active sulforaphane.
The product is scheduled for market entry in Q2 2025, targeting the functional foods and beverages sector. The company positions this innovation as a potential catalyst for expanding the broccoli-derived wellness market, with applications across multiple sectors including anti-tumor therapies, mental health support, and digestive health management.
Bon Natural Life (Nasdaq: BON) ha annunciato una svolta nella nutrizione derivata dal broccolo con il loro sistema di co-consegna Glucoraphanin-Myrosinase in attesa di brevetto. Questa innovazione biotecnologica migliora la bioattività del glucorafano, un composto chiave nel broccolo che si trasforma in sulforafano.
La tecnologia affronta il precedente processo di conversione inefficiente del glucorafano in sulforafano, noto per le sue proprietà anti-cancro, miglioramento del sonno, neuroprotezione, potenziamento digestivo, anti-infiammatorie, antiossidanti e anti-invecchiamento. La soluzione dell'azienda garantisce un'attivazione enzimatica ottimale all'interno del corpo, raggiungendo una maggiore efficienza di conversione in sulforafano bioattivo.
Il prodotto è programmato per entrare nel mercato nel secondo trimestre del 2025, mirando al settore degli alimenti e delle bevande funzionali. L'azienda posiziona questa innovazione come un potenziale catalizzatore per l'espansione del mercato del benessere derivato dal broccolo, con applicazioni in diversi settori tra cui terapie anti-tumorali, supporto alla salute mentale e gestione della salute digestiva.
Bon Natural Life (Nasdaq: BON) ha anunciado un avance en la nutrición derivada del brócoli con su sistema de co-entrega Glucoraphanin-Myrosinase pendiente de patente. Esta innovación biotecnológica mejora la bioactividad de la glucorafamina, un compuesto clave en el brócoli que se convierte en sulforafano.
La tecnología aborda el proceso de conversión ineficiente anterior de glucorafamina a sulforafano, conocido por sus propiedades anticancerígenas, mejora del sueño, neuroprotección, mejora digestiva, antiinflamatorias, antioxidantes y antienvejecimiento. La solución de la empresa asegura una activación enzimática óptima dentro del cuerpo, logrando una mayor eficiencia de conversión a sulforafano bioactivo.
El producto está programado para entrar en el mercado en el segundo trimestre de 2025, dirigido al sector de alimentos y bebidas funcionales. La empresa posiciona esta innovación como un posible catalizador para la expansión del mercado de bienestar derivado del brócoli, con aplicaciones en múltiples sectores, incluidas terapias anti-tumorales, apoyo a la salud mental y gestión de la salud digestiva.
본 내추럴 라이프 (Nasdaq: BON)는 특허 출원 중인 글루코라파닌-미로시나제 공동 전달 시스템을 통해 브로콜리 유래 영양소에서 혁신적인 발전을 발표했습니다. 이 생명공학 혁신은 브로콜리의 주요 성분인 글루코라파닌의 생체 활성을 향상시킵니다. 글루코라파닌은 설포라판으로 전환됩니다.
이 기술은 글루코라파닌이 설포라판으로 전환되는 이전의 비효율적인 과정을 해결합니다. 설포라판은 항암, 수면 개선, 신경 보호, 소화 개선, 항염증, 항산화 및 노화 방지 특성으로 잘 알려져 있습니다. 회사의 솔루션은 체내에서 최적의 효소 활성화를 보장하여 생체 활성 설포라판으로의 전환 효율성을 높입니다.
이 제품은 2025년 2분기에 시장에 출시될 예정이며, 기능성 식품 및 음료 부문을 목표로 하고 있습니다. 이 회사는 이 혁신을 브로콜리 유래 웰니스 시장의 확장을 위한 잠재적 촉매제로 위치시키며, 항종양 치료, 정신 건강 지원 및 소화 건강 관리 등 여러 분야에 적용될 수 있습니다.
Bon Natural Life (Nasdaq: BON) a annoncé une avancée dans la nutrition dérivée du brocoli avec son système de co-livraison Glucoraphanin-Myrosinase en attente de brevet. Cette innovation biotechnologique améliore la bioactivité du glucoraphanine, un composé clé du brocoli qui se transforme en sulforaphane.
La technologie traite le processus de conversion inefficace du glucoraphanine en sulforaphane, connu pour ses propriétés anticancéreuses, d'amélioration du sommeil, neuroprotectrices, d'amélioration de la digestion, anti-inflammatoires, antioxydantes et anti-âge. La solution de l'entreprise garantit une activation enzymatique optimale dans le corps, atteignant une efficacité de conversion supérieure en sulforaphane bioactif.
Le produit est prévu pour entrer sur le marché au deuxième trimestre de 2025, ciblant le secteur des aliments et des boissons fonctionnels. L'entreprise positionne cette innovation comme un catalyseur potentiel pour l'expansion du marché du bien-être dérivé du brocoli, avec des applications dans plusieurs secteurs, y compris les thérapies anti-tumorales, le soutien à la santé mentale et la gestion de la santé digestive.
Bon Natural Life (Nasdaq: BON) hat einen Durchbruch in der brokkoli-basierten Ernährung mit ihrem patentierten Glucoraphanin-Myrosinase-Co-Delivery-System angekündigt. Diese biotechnologische Innovation verbessert die Bioaktivität von Glucoraphanin, einer Schlüsselverbindung im Brokkoli, die sich in Sulforaphan umwandelt.
Die Technologie adressiert den zuvor ineffizienten Umwandlungsprozess von Glucoraphanin zu Sulforaphan, das für seine krebsbekämpfenden, schlaffördernden, neuroprotektiven, verdauungsfördernden, entzündungshemmenden, antioxidativen und altershemmenden Eigenschaften bekannt ist. Die Lösung des Unternehmens gewährleistet eine optimale enzymatische Aktivierung im Körper und erreicht eine höhere Umwandlungseffizienz zu bioaktivem Sulforaphan.
Das Produkt ist für die Markteinführung im zweiten Quartal 2025 geplant und zielt auf den Bereich der funktionalen Lebensmittel und Getränke ab. Das Unternehmen positioniert diese Innovation als potenziellen Katalysator für die Expansion des brokkoli-basierten Wellnessmarktes mit Anwendungen in mehreren Sektoren, einschließlich Tumortherapien, Unterstützung der psychischen Gesundheit und Verwaltung der Verdauungsgesundheit.
- Patent-pending technology addressing a significant market challenge
- Targeting multi-billion dollar market opportunity across multiple sectors
- Planned Q2 2025 market entry with clear commercialization timeline
- Enhanced bioavailability solving key industrial application challenge
- Product not yet commercialized - future market success uncertain
- No specific efficacy data or clinical validation metrics provided
Insights
BON's development of a Glucoraphanin-Myrosinase co-delivery system represents a notable approach to solving a well-documented challenge in nutritional biochemistry. The core innovation addresses the inefficient conversion of glucoraphanin to sulforaphane, which has long the practical applications of broccoli's bioactive compounds.
The technical significance lies in the enzyme stability and controlled release mechanisms that must be precisely engineered for this system to function effectively. While the patent-pending status indicates proprietary protection is being pursued, the technology still faces several hurdles before proven commercial viability - including stability during food processing, shelf-life considerations, and demonstration of enhanced bioavailability in human subjects.
Sulforaphane's diverse bioactivities are supported by preclinical research, but the translation to clinically meaningful outcomes requires more substantial evidence. The application in functional foods represents a lower regulatory barrier than pharmaceutical applications, potentially accelerating market entry.
What separates truly successful delivery systems in this space is manufacturing scalability and cost-effectiveness - factors not addressed in this announcement. The Q2 2025 timeline suggests the technology has progressed beyond early development but still requires significant optimization before full commercialization.
This announcement positions BON to potentially capture value in the growing functional food ingredients market, where proprietary delivery technologies command premium pricing. The company is strategically targeting a consumer pain point - the gap between broccoli's perceived health benefits and the biological reality of poor compound bioavailability.
The multi-billion dollar market reference lacks specificity but aligns with broader trends in nutraceuticals and functional ingredients. The innovation's true commercial potential hinges on several factors not detailed in the announcement: production costs, pricing strategy, target customer segments (B2B ingredient sales vs. consumer products), and go-to-market partnerships.
For context, BON's current market capitalization of
The delivery system's versatility across multiple applications (anti-tumor, mental health, digestive health) suggests a platform technology approach that could yield multiple product lines. This diversification strategy reduces dependency on any single application while potentially extending intellectual property value.
Without specific revenue projections or development cost details, the announcement signals innovation intent but provides insufficient information to forecast meaningful financial impact.
XI’AN, China, April 08, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (Nasdaq: BON) ("BON" or "the Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, announced our biotech innovation addresses nutritional critical challenges through a patent-pending Glucoraphanin-Myrosinase co-delivery system that significantly enhances the bio-activity of glucoraph anin, a key bio-active compound in broccoli.
Broccoli stands as a nutrient-rich super food containing glucoraphanin-the vegetable's key bio-active compound that could metabolically converted into sulforaphane within biological systems. Sulforaphane is associated with diverse bio-active properties ranging from anti-cancer, sleep improvement, neuroprotection, digestive system enhancement, anti-inflammatory, antioxidant, and anti-aging effects. However, this precursor molecule requires enzymatic conversion to sulforaphane, the active form that delivers these effects. This biological conversion process proves challenging and inefficient, posing a significant obstacle to effective nutritional utilization and commercial application.
This breakthrough technology ensures optimal enzymatic activation within the body, achieving unprecedented conversion efficiency to bio-active sulforaphane. By industrially solving the fundamental bio-availability issue, we're positioned to revolutionize functional food applications. Driven by the compound’s diverse applications with significant potential in anti-tumor therapies, mental health support, and digestive health management, ongoing technological innovations—specifically those enhancing efficiency, usability, and user compliance—are expected to unlock a multi-billion-dollar for sulforaphane across emerging sectors.
Yongwei Hu, CEO & Chairman of Bon, stated,“scheduled for Q2 2025 market entry, this advancement promises to transform and notably broaden the broccoli-derived wellness market, particularly in functional foods and beverages. This innovation holds immense market potential and is poised to fuel significant industry expansion through its unique value proposition.”
About Bon Natural Life Limited ("BON")
BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company’s website at http://www.bnlus.com.
For more information, please contact:
Cindy Liu | IR
Email: bonnatural@appchem.cn
Safe Harbor Statement
This press release contains certain statements that may include "forward-looking statements." All statements other than statements of historical fact included herein are "forward-looking statements." These forward-looking statements are often identified by the use of forward-looking terminology such as "believes,""expects" or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company's actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company's periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.
FAQ
When will BON's new glucoraphanin delivery system launch?
What health benefits does BON's broccoli-derived compound target?
What problem does BON's new delivery system solve?
Which markets will BON's new glucoraphanin technology target?
